Amy Burd

950 total citations
19 papers, 467 citations indexed

About

Amy Burd is a scholar working on Molecular Biology, Hematology and Cancer Research. According to data from OpenAlex, Amy Burd has authored 19 papers receiving a total of 467 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 7 papers in Hematology and 5 papers in Cancer Research. Recurrent topics in Amy Burd's work include Acute Myeloid Leukemia Research (7 papers), Pharmacological Receptor Mechanisms and Effects (4 papers) and Receptor Mechanisms and Signaling (4 papers). Amy Burd is often cited by papers focused on Acute Myeloid Leukemia Research (7 papers), Pharmacological Receptor Mechanisms and Effects (4 papers) and Receptor Mechanisms and Signaling (4 papers). Amy Burd collaborates with scholars based in United States and Germany. Amy Burd's co-authors include Horace H. Loh, Ping‐Yee Law, Chia‐Yu Chang, Rachid El Kouhen, Wei Wang, Lee H. Dicker, Jonathan Solberg, Mark Lynch, Hong Shi and Richard Gedrich and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Amy Burd

17 papers receiving 459 citations

Peers

Countries citing papers authored by Amy Burd

Since Specialization

Citations

This map shows the geographic impact of Amy Burd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Burd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Burd more than expected).

Fields of papers citing papers by Amy Burd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Burd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Burd. The network helps show where Amy Burd may publish in the future.

Co-authorship network of co-authors of Amy Burd

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Burd. A scholar is included among the top collaborators of Amy Burd based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Burd. Amy Burd is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Abstract C114: Discovery of a Novel, Selective Brain-Penetrant CDK2 inhibitor for targeted cancer therapy 2025 ·Molecular Cancer Therapeutics ·(unknown), (unknown), Рубен Карапетян, (unknown), Елена А. Буланова, (unknown), Nikolay Savchuk, Iain Dukes, Amy Burd	0
2	Development of ZE66-0205, a Novel MALT1 Degrader for Treatment of B-Cell Malignancies 2024 ·Blood ·Sara Elgamal, (unknown), (unknown), (unknown), (unknown), Megan Johnstone, Jianmin Pan, N. Shesh, Alexander Khvat, Рубен Карапетян, (unknown), Елена А. Буланова, (unknown), Nikolay Savchuk, Iain Dukes, Amy Burd, Erin Hertlein, John C. Byrd	1
3	Real‐world genomic testing and treatment patterns of newly diagnosed adult acute myeloid leukemia patients within a comprehensive health system 2023 ·Cancer Medicine ·John C. Byrd, Jennifer Gatz, (unknown), Alice S. Mims, Uma Borate, (unknown), Theophilus J. Gana, Amy Burd	1
4	Is Disease Response a Patient-Centered Clinical Trial Endpoint in Acute Myeloid Leukemia: Differences in Symptom Burden and Physical Function By Response Status in the Beat-AML Master Trial 2022 ·Blood ·Antonia V. Bennett, Xianming Tan, Matthew C. Foster, Daniel R. Richardson, Ashley Leak Bryant, William A. Wood, (unknown), Alice S. Mims, Uma Borate, Amy Burd	1
5	A phase 1b/2 study of TP-0903 and decitabine targeting mutant TP53 and/or complex karyotype in patients with untreated acute myeloid leukemia ≥ age 60 years: Phase 1b interim results. 2022 ·Journal of Clinical Oncology ·Alice S. Mims, (unknown), Eric D. Eisenmann, Daelynn R. Buelow, Ronan Swords, Matthew C. Foster, Tara L. Lin, Maria R. Baer, Tibor Kovacsovics, Zeina Al‐Mansour, Mona Stefanos, (unknown), Timothy F. Chen, (unknown), Uma Borate, Brian Druker, Amy Burd, Ross L. Levine, Sharyn D. Baker, John C. Byrd	4
6	A precision medicine classification for treatment of acute myeloid leukemia in older patients 2021 ·Journal of Hematology & Oncology ·Alice S. Mims, Jessica Kohlschmidt, Uma Borate, James S. Blachly, Shelley Orwick, Ann-Kathrin Eisfeld, Dimitrios Papaioannou, Deedra Nicolet, Krzysztof Mrózek, Eytan M. Stein, Bhavana Bhatnagar, Richard M. Stone, Jonathan E. Kolitz, Eunice S. Wang, Bayard L. Powell, Amy Burd, Ross L. Levine, Brian Druker, Clara D. Bloomfield, John C. Byrd	10
7	Challenges and approaches to implementing master/basket trials in oncology 2019 ·Blood Advances ·Amy Burd, Richard L. Schilsky, John C. Byrd, Ross L. Levine, Vassiliki A. Papadimitrakopoulou, Roy S. Herbst, Mary W. Redman, Brian Druker, David R. Gandara	9
8	Enasidenib Is Highly Active in Previously Untreated IDH2 Mutant AML: Early Results from the Beat AML Master Trial 2018 ·Blood ·Eytan M. Stein, Abigail B. Shoben, Uma Borate, Maria R. Baer, Wendy Stock, Prapti A. Patel, Tibor Kovacsovics, William Blum, Jo‐Anne Vergilio, Nyla A. Heerema, (unknown), Sonja Marcus, Mona Stefanos, (unknown), Brian Druker, Amy Burd, John C. Byrd, Ross L. Levine, Alice S. Mims	11
9	A Next-Generation Sequencing-Based Karyotyping Algorithm Reveals the Genomic Structure of Acute Myeloid Leukemia 2018 ·Blood ·Dean C. Pavlick, Meagan Montesion, Nyla A. Heerema, Eric A. Severson, Timothy Brennan, Garrett M. Frampton, (unknown), John C. Byrd, Ross L. Levine, Amy Burd, Jo‐Anne Vergilio, Lee A. Albacker	0
10	Pharmacokinetic and pharmacodynamic analysis of gastric cancer patients treated with telatinib. 2011 ·Journal of Clinical Oncology ·Amy Burd, J. Castillo, (unknown), Matthew White, Jaffer A. Ajani, Ali Fattaey, Lori Kunkel	1
11	ACTB-1003: An oral kinase inhibitor targeting cancer mutations (FGFR), angiogenesis (VEGFR2, TEK), and induction of apoptosis (RSK and p70S6K). 2010 ·Journal of Clinical Oncology ·Krish Patel, Ali Fattaey, Amy Burd	4
12	Antitumor activity of sorafenib in FLT3-driven leukemic cells 2007 ·Leukemia ·Daniel Auclair, David F. Miller, (unknown), W C Pickett, (unknown), (unknown), (unknown), Dean Wilkie, Amy Burd, Hong Shi, (unknown), Richard Gedrich, Laura Abriola, Hema Vasavada, Mark Lynch, Jacques Dumas, Pamela A. Trail, S M Wilhelm	134
13	Analysis of transcription and protein expression changes in the 786-O human renal cell carcinoma tumor xenograft model in response to treatment with the multi-kinase inhibitor sorafenib (BAY 43-9006) 2006 ·Cancer Research ·Joan Levy, (unknown), Déborah Braun, Mary DeRome, (unknown), Hong Shi, Daniel C. Weaver, Yong S. Chang, Elizabeth Bortolon, Arris J. Henderson, (unknown), Amy Burd, James J. Elting, Mark Lynch, Sanjeeva Reddy, Scott M. Wilhelm	25
14	572 POSTER Sorafenib (BAY 43-9006) inhibits imatinib-resistant mutant KIT signaling 2006 ·European Journal of Cancer Supplements ·Richard Gedrich, Elizabeth Sullivan, Hong Shi, Matthew Brown, (unknown), Amy Burd, (unknown), (unknown)	1
15	Assembly of Major Histocompatability Complex (MHC) Class II Transcription Factors: Association and Promoter Recognition of RFX Proteins 2004 ·Biochemistry ·Amy Burd, Richard H. Ingraham, (unknown), Rachel Kroe‐Barrett, James J. Crute, Christine A. Grygon	14
16	Phosphorylation of Ser363, Thr370, and Ser375 Residues within the Carboxyl Tail Differentially Regulates μ-Opioid Receptor Internalization 2001 ·Journal of Biological Chemistry ·Rachid El Kouhen, Amy Burd, (unknown), Chia‐Yu Chang, Ping‐Yee Law, Horace H. Loh	106
17	Receptor Density and Recycling Affect the Rate of Agonist-Induced Desensitization of μ-Opioid Receptor 2000 ·Molecular Pharmacology ·Ping‐Yee Law, (unknown), (unknown), Lee H. Dicker, Jonathan Solberg, Wei Wang, (unknown), Amy Burd, Horace H. Loh	92
18	Receptor Density and Recycling Affect the Rate of Agonist-Induced Desensitization of μ-Opioid Receptor 2000 ·Molecular Pharmacology ·Ping‐Yee Law, (unknown), (unknown), Lee H. Dicker, Jonathan Solberg, Wei Wang, (unknown), Amy Burd, Horace H. Loh	11
19	Identification of Serine 356 and Serine 363 as the Amino Acids Involved in Etorphine-induced Down-regulation of the μ-Opioid Receptor 1998 ·Journal of Biological Chemistry ·Amy Burd, (unknown), (unknown), Horace H. Loh, Ping‐Yee Law	42

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact